Daré Bioscience, Inc. (DARE) Q2 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call presents a mixed outlook. Positive factors include strategic partnerships, grant funding, and a strengthened balance sheet. However, financial constraints, regulatory hurdles, and market competition pose significant risks. The company's dual-path strategy and product pipeline are promising, but uncertainties in execution and economic conditions temper optimism. Overall, the sentiment is neutral, with potential for both positive and negative market reactions.
Key Financial Performance
Cash and Cash Equivalents $5 million as of June 30, 2025, with a working capital deficit of approximately $12.6 million. After the quarter ended, the company received approximately $17.6 million in net proceeds from sales of common stock and a $6 million grant payment, significantly strengthening the balance sheet.
General and Administrative (G&A) Expenses $2.4 million in Q2 2025, compared to $2.5 million in Q2 2024. The year-over-year decrease was primarily due to reductions in personnel costs, stock-based compensation expense, and general corporate overhead, partially offset by an increase in professional services expense.
Research and Development (R&D) Expenses $1.4 million in Q2 2025, a 71% decrease compared to Q2 2024. The decrease was primarily due to an increase in contra R&D expenses (reductions to R&D expenses recognized due to nondilutive funding awards) and decreases in manufacturing costs related to Ovaprene and development costs related to Sildenafil cream. This was partially offset by increases in costs related to other clinical and preclinical R&D programs, including DARE-HPV and DARE-LARC1.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
DARE to PLAY Sildenafil cream: On track for Q4 2025 launch via 503B outsourcing facility. Positioned as a significant innovation in women's sexual health, addressing arousal concerns. Early awareness campaign and provider webinar highlight its potential as a near-term revenue driver.
Ovaprene: Phase III trial progressing with no safety concerns. Potential first-in-category, hormone-free monthly contraceptive. Bayer may commercialize post-trial with potential $20 million payment and up to $310 million in milestone payments.
DARE-HRT1: Proprietary intravaginal ring for hormone therapy. Dual commercialization path targeting late 2026 availability. Positioned in the $4.5 billion hormone therapy market.
Vaginal probiotics: Nonprescription products to support vaginal microbiome health. Launch planned post-DARE to PLAY introduction, diversifying commercial platform.
Partnership with Rosy Wellness: Launched direct-to-patient awareness campaign for DARE to PLAY, indicating significant market interest.
Bayer partnership for Ovaprene: Potential exclusive U.S. commercialization rights with significant financial milestones.
Dual-path strategy: Combines 503B compounding commercialization with FDA approval pursuit, enabling efficient market entry and long-term value creation.
Grant-funded programs: Advancing DARE-HPV and DARE-LARC1 with nondilutive funding, targeting unmet needs in women's health.
Diversification of commercial platform: Expanding into nonprescription products like vaginal probiotics to complement prescription offerings.
Focus on innovation in women's health: Bridging gaps in women's health with science-backed solutions and addressing unmet needs in contraception, HPV, and preterm birth.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Regulatory hurdles: Discussions with the FDA are ongoing to define acceptable endpoints for a future FDA registration path for DARE to PLAY Sildenafil cream. This indicates potential delays or challenges in obtaining FDA approval.
Financial constraints: The company ended the quarter with $5 million in cash and cash equivalents and a working capital deficit of $12.6 million, which could impact its ability to execute its strategy effectively.
Market competition: DARE to PLAY Sildenafil cream is entering a market where clinical evaluation of topical Sildenafil formulations has been lacking, but competition from existing erectile dysfunction drugs and other innovations could pose challenges.
Supply chain and commercialization risks: The company is relying on a 503B outsourcing facility for the launch of DARE to PLAY Sildenafil cream and DARE-HRT1, which could face operational or supply chain disruptions.
Dependence on third-party agreements: The potential $20 million payment and royalty payments for Ovaprene are subject to a third party's minority interest under a royalty purchase agreement, which could complicate financial outcomes.
Economic uncertainties: The company’s reliance on grant funding and nondilutive capital for several programs highlights potential vulnerabilities to economic changes or funding availability.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
DARE to PLAY Sildenafil cream launch: The company remains on track to support the commercial availability of DARE to PLAY Sildenafil cream through a 503B outsourcing facility in Q4 2025. This is expected to be a significant milestone in women's sexual health.
Ovaprene Phase III trial: The independent Data and Safety Monitoring Board recommended the continuation of the Phase III trial as planned. The interim pregnancy rate aligns with expectations, and the product has the potential to address a significant unmet need for hormone-free contraception. Bayer may commercialize the product post-trial, with potential milestone payments and royalties for Daré.
DARE-HRT1 commercialization: The company is pursuing a dual commercialization pathway for DARE-HRT1, targeting availability via a 503B outsourcing facility in late 2026. This product is positioned to address the $4.5 billion compounded hormone therapy market.
Vaginal probiotics launch: Daré plans to launch two nonprescription vaginal probiotics to support vaginal microbiome health following the launch of DARE to PLAY later this year.
Grant-funded clinical programs: Programs like DARE-HPV and DARE-LARC1 are advancing with nondilutive funding. DARE-HPV targets high-risk HPV infection, while DARE-LARC1 is a preclinical long-acting contraceptive with remote control features.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Review of Unclear Management Responses
A:
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
AASECT discussion
ARPA award
Association Nurse
Bar National
Bayer discretion
Bayer right
Bioscience Therapeutics
Daré Bioscience
Financial Results
HRT
Haring Layton
Health
LARC
Layton Chief
MarDee Haring
Ovaprene potential
RD
Sexual
Women
completion
control
difficulty
expense
formulation cream
gap woman
hormone therapy
increase
interest
payment
pregnancy rate
probiotic
product prescription
royalty
sale
today Daré
track launch
woman arousal
DARE Transcript
Daré Bioscience, Inc. (DARE) Q1 2026 Earnings Call Transcript
Unknown5-14
The earnings call indicates a mixed outlook. The 25% revenue growth is positive, but the net loss and increased R&D expenses raise concerns. The dual path strategy offers potential but carries regulatory and execution risks. No new partnerships or changes in guidance were mentioned, and shareholder return plans were not discussed. Without information on market cap, a neutral sentiment is appropriate, reflecting balanced positive and negative factors.
Daré Bioscience, Inc. (DARE) Q4 2025 Earnings Call Transcript
Unknown3-26
The company's reliance on non-dilutive funding and limited working capital pose sustainability concerns. Competitive pressures and strategic execution risks further exacerbate these issues. Despite decreasing expenses, the potential for constrained operational flexibility and unclear management responses in the Q&A section contribute to a negative sentiment. The lack of new partnerships or strong positive catalysts, coupled with competitive pressures in a challenging market, suggests a negative stock price movement in the short term.
Daré Bioscience, Inc. (DARE) Q3 2025 Earnings Call Transcript
Unknown11-13
The earnings call reveals financial constraints with limited cash reserves and working capital, increased G&A expenses, and decreased R&D spending. While management is optimistic about product launches and partnerships, the market entry challenges, competitive pressures, and supply chain risks pose significant uncertainties. The Q&A section highlights the company's strategic focus but also underscores financial limitations and the need for careful execution. Overall, the negative financial health and strategic risks outweigh positive developments, leading to a negative sentiment rating.
Daré Bioscience, Inc. (DARE) Q2 2025 Earnings Call Transcript
Unknown8-14
The earnings call presents a mixed outlook. Positive factors include strategic partnerships, grant funding, and a strengthened balance sheet. However, financial constraints, regulatory hurdles, and market competition pose significant risks. The company's dual-path strategy and product pipeline are promising, but uncertainties in execution and economic conditions temper optimism. Overall, the sentiment is neutral, with potential for both positive and negative market reactions.
DARE Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
